title: Interstitial Pneumonitis after Treatment with Pemetrexed for Non-small Cell Lung Cancer.
abstract: Pemetrexed is approved as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) with cisplatin and as a single agent for second-line treatment or for patients who show no disease progression after four cycles of platinum-based doublet induction chemotherapy as maintenance therapy. Pemetrexed has a modest toxicity profile and has not traditionally been regarded as a cause of interstitial pneumonitis. Here, we report on a rare case of pemetrexed-induced pneumonitis in a patient with NSCLC.
authors.affiliation: Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon, Korea.
authors.forename: Kyeong-Hyun
authors.initials: KH
authors.lastname: Kim
authors.forename: Seo-Young
authors.initials: SY
authors.lastname: Song
authors.forename: Kyu-Hyoung
authors.initials: KH
authors.lastname: Lim
authors.forename: Seon-Sook
authors.initials: SS
authors.lastname: Han
authors.forename: Se-Hyun
authors.initials: SH
authors.lastname: Kim
authors.forename: Jun Hwi
authors.initials: JH
authors.lastname: Cho
authors.forename: Chan Woo
authors.initials: CW
authors.lastname: Park
authors.forename: Seoungkoo
authors.initials: S
authors.lastname: Lee
authors.forename: Hui-Young
authors.initials: HY
authors.lastname: Lee
keywords: Adenocarcinoma; Drug therapy; Interstitial lung diseases; Non-small-cell lung carcinoma; Pemetrexed